Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.

Aya F, Fernández-Martínez A, Gaba L, Victoria I, Tosca M, Carrera C, Prat A, Arance A.

Immunotherapy. 2016 Jun;8(6):687-92. doi: 10.2217/imt-2015-0025. Epub 2016 Apr 26.

PMID:
27115320
2.

Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.

Day F, Kumar M, Fenton L, Gedye C.

J Immunother. 2017 Jan;40(1):36-38.

PMID:
27684455
3.

Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.

Spain L, Larkin J.

Immunotherapy. 2016 Jun;8(6):677-9. doi: 10.2217/imt.16.6. No abstract available.

4.

Safety of immune checkpoint inhibitors in Chinese patients with melanoma.

Wen X, Wang Y, Ding Y, Li D, Li J, Guo Y, Peng R, Zhao J, Zhang X, Zhang XS.

Melanoma Res. 2016 Jun;26(3):284-9. doi: 10.1097/CMR.0000000000000256.

PMID:
27116334
5.

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.

Hao C, Tian J, Liu H, Li F, Niu H, Zhu B.

Medicine (Baltimore). 2017 Jun;96(26):e7325. doi: 10.1097/MD.0000000000007325. Review.

6.

Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.

Zecchini JM, Kim S, Yum K, Friedlander P.

J Immunother. 2018 Jan;41(1):39-41. doi: 10.1097/CJI.0000000000000184.

PMID:
28926356
7.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
8.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

9.

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB.

Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Review. Erratum in: Pharmacotherapy. 2015 Dec;35(12):1205.

PMID:
26497482
10.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, Ascierto PA, Salama AK, Margolin KA, Loquai C, Eigentler TK, Gangadhar TC, Carlino MS, Agarwala SS, Moschos SJ, Sosman JA, Goldinger SM, Shapira-Frommer R, Gonzalez R, Kirkwood JM, Wolchok JD, Eggermont A, Li XN, Zhou W, Zernhelt AM, Lis J, Ebbinghaus S, Kang SP, Daud A.

Lancet Oncol. 2015 Aug;16(8):908-18. doi: 10.1016/S1470-2045(15)00083-2. Epub 2015 Jun 23.

PMID:
26115796
11.

Pembrolizumab use for the treatment of advanced melanoma.

Specenier P.

Expert Opin Biol Ther. 2017 Jun;17(6):765-780. doi: 10.1080/14712598.2017.1309388. Epub 2017 Apr 3.

PMID:
28323504
12.

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem S, Keller F, Rüesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L.

J Immunother. 2016 Nov/Dec;39(9):379-382.

13.

[Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].

Robert C, Mateus C.

Bull Acad Natl Med. 2014 Feb;198(2):297-308. French.

PMID:
26263705
14.

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators.

N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.

15.

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.

Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, Heinzerling L, Ugurel S, Pföhler C, Gesierich A, Livingstone E, Satzger I, Kähler KC; German Dermatooncology Group (DeCOG).

Eur J Cancer. 2017 Apr;75:24-32. doi: 10.1016/j.ejca.2016.12.038. Epub 2017 Feb 16.

PMID:
28214654
16.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

17.

Programmed death-1 & its ligands: promising targets for cancer immunotherapy.

Shrimali RK, Janik JE, Abu-Eid R, Mkrtichyan M, Khleif SN.

Immunotherapy. 2015;7(7):777-92. doi: 10.2217/imt.15.49. Epub 2015 Aug 7. Review.

PMID:
26250412
18.

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.

Larkin J, Lao CD, Urba WJ, McDermott DF, Horak C, Jiang J, Wolchok JD.

JAMA Oncol. 2015 Jul;1(4):433-40. doi: 10.1001/jamaoncol.2015.1184.

PMID:
26181250
19.

Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1.

Simeone E, Ascierto PA.

J Immunotoxicol. 2012 Jul-Sep;9(3):241-7. doi: 10.3109/1547691X.2012.678021. Epub 2012 Apr 23. Review.

PMID:
22524673
20.

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Buchbinder EI, Desai A.

Am J Clin Oncol. 2016 Feb;39(1):98-106. doi: 10.1097/COC.0000000000000239. Review.

Supplemental Content

Support Center